On 23rd January 2020 at the World Economic Forum Annual Meeting in Davos, the Access to Medicine Foundation, the FAIRR Initiative and the UK Government launched a new initiative – Investor Action on Antimicrobial Resistance (IAAMR) - focused on tackling the global threat of drug-resistant infections. IAAMR is currently supported by 17 investors with over USD $12 trillion in AUM. The Initiative is entering its next phase and is seeking to grow its membership. If you are an investor interested in learning more about AMR and the role you can play please get in touch.

The main aim of the Investor Action on AMR initiative is to leverage investor influence to combat drug-resistant superbugs – an urgent public health challenge associated with an estimated 4.95 million deaths globally in 2019 alone and estimated to cost the world $100 trillion USD in global economic losses.

The COVID-19 pandemic not only demonstrated the significant impacts that human health risks have on economies and societies worldwide, but also the importance of investing in preventative healthcare including safeguarding our ability to treat infectious diseases with existing antibiotics. The threat of AMR was compounded further during the pandemic and the World Bank estimates that the material risk of AMR will result in cumulative global economic output losses of 100 trillion USD by 2050. To safeguard society, economies, and the long-term value of investment portfolios, we are encouraging investors to formally assess and integrate AMR risks, opportunities and impacts using a holistic and multi-sectoral ‘One Health’ approach.